NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, has been selected as an expert speaker and will participate in multiple presentations, including a keynote session, during the 2nd Annual NASH Summit being held at the Revere Hotel Boston Common in Boston on April 23-25, 2018. Details of Dr. Traber’s sessions can be found below.
- Tuesday, April 24, 20185:15 p.m.: Panel Discussion - Non-Invasive Biomarkers - How Near Are We?
- Wednesday, April 25, 20183:30 p.m.: Keynote – Clinical Trials & Endpoints in NASH Cirrhosis
The NASH Summit is the industry’s most comprehensive conference on drug development for non-alcoholic steatohepatitis (NASH) focused on drug discovery through late stage clinical development. It brings together thought leaders from across the industry to give detailed presentations across multiple streams of learning in the NASH sector.
Positive Results in NASH Cirrhosis
Galectin Therapeutics recently completed a Phase 2b clinical trial (NASH-CX) on GR-MD-02, the Company’s proprietary polysaccharide pharmaceutical preparation that inhibits galectin proteins. There were statistically significant and clinically relevant positive effects of GR-MD-02 on portal hypertension (hepatic venous pressure gradient or HVPG) and other liver biopsy parameters in patients with NASH cirrhosis without esophageal varices following one year of therapy. Patients without esophageal varices comprise about 50 percent of the total population of patients with NASH cirrhosis, and is estimated to be 2.5 million people in the United States. This group of patients is readily diagnosed by endoscopy which is already part of the standard of care for patients with NASH cirrhosis. The drug was well tolerated during this one-year trial. The Company believes that this is the first randomized clinical trial of any drug to demonstrate clinically meaningful positive effects in this important group of patients. Full details of Galectin’s NASH-CX trial can be found in a supplemental slide deck of the Galectin corporate presentation on the homepage of its website.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Jack Callicutt, Chief Financial Officer
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
Source: Galectin Therapeutics Inc.